2. AstraZeneca PLC (NYSE:AZN)
Market Cap $256.18 billion | Beta 0.32 | Net Profit Margin 17.02%
Oncology and Rare Disease Support the Growth Story
AstraZeneca PLC (NYSE: AZN) combines a comparatively low supplied beta with an expanding pharmaceutical business. First-half 2026 revenue reached approximately $30.7 billion, increasing 6% at constant exchange rates, with double-digit growth in oncology and rare disease.
That combination matters for investors seeking defensive healthcare stocks with growth potential. Cancer medicines and rare disease treatments provide exposure to specialized areas of healthcare, while the commercial portfolio generates revenue alongside ongoing clinical development.
Profit growth outpaced revenue growth on the company’s core measures. First-half core operating profit and core earnings per share both increased 11% at constant exchange rates. Core EPS reached $5.21, while core operating profit totaled approximately $10.5 billion. These adjusted measures help explain operating performance, although they should be assessed alongside reported results.
Pipeline progress supplied further support. Management highlighted six positive Phase 3 programs and eight first approvals in major markets during the first half. Successful trials and regulatory approvals can broaden a medicine’s commercial opportunity, but their financial contribution still depends on launches, reimbursement, prescribing, and competition.
The investment appeal is therefore a combination of current earnings and future product opportunities. Clinical progress strengthens that case, while the supplied 17.02% net profit margin provides a separate indication of profitability. Neither measure, by itself, establishes that the shares are inexpensive.
Ranking Rationale
AstraZeneca PLC (NYSE: AZN) ranks second because its supplied beta of 0.32 is lower than those of the three companies below it. Its $256.18 billion market capitalization and 17.02% net profit margin also exceed the screen’s thresholds. The position reflects historical market sensitivity rather than a forecast of superior share-price performance.
